- PROTOPANAXTRIOL
-
- $32514.00
-
2026-07-15
- CAS:34080-08-5
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 1000kg
|
| | PROTOPANAXTRIOL Basic information |
| | PROTOPANAXTRIOL Chemical Properties |
| Melting point | 242-244 °C | | Boiling point | 590.0±50.0 °C(Predicted) | | density | 1.079 | | storage temp. | -20°C Freezer | | solubility | Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly) | | form | Solid | | pka | 14.73±0.70(Predicted) | | color | Off-White | | InChIKey | SHCBCKBYTHZQGZ-NSMZZYIQNA-N | | SMILES | O[C@H]1[C@H]2[C@@]([C@]3([C@@H]([C@@]4([C@@H]([C@H](C3)O)C([C@H](CC4)O)(C)C)C)C1)C)(CC[C@@H]2[C@@](O)(CCC=C(C)C)C)C | | LogP | 5.890 (est) |
| WGK Germany | 3 | | HS Code | 29061990 | | Storage Class | 11 - Combustible Solids |
| | PROTOPANAXTRIOL Usage And Synthesis |
| Chemical Properties | White crystalline powder, soluble in organic solvents such as methanol, ethanol, and DMSO, derived from ginseng. | | Uses | (20S)-Protopanaxatriol acts as an inhibitor in the production of corticosteroids in fasciculata cells. Used in the clinical treatment of heart diseases. | | Definition | ChEBI: Protopanaxatriol is a tetracyclic triterpenoid sapogenin (isolated from ginseng and notoginseng) that is that is dammarane which is substituted by hydroxy groups at the 3beta, 6alpha, 12beta and 20 pro-S positions and in which a double bond has been introduced at the 24-25 position. It has a role as a metabolite. It is a tetracyclic triterpenoid, a sapogenin, a 3beta-hydroxy steroid, a 12beta-hydroxy steroid, a 6alpha-hydroxy steroid and a 3beta-hydroxy-4,4-dimethylsteroid. It derives from a hydride of a dammarane. | | Biological Activity | A metabolites of ginsenoside, protopanaxatriol (g-PPT), could modulate endothelial cell functions through the glucocorticoid receptor (GR) and oestrogen receptor (ER). | | in vivo | (20S)-Protopanaxatriol (10mg/kg; i.p.; daily for four weeks) synergizes with Gefitinib to inhibit xenograft growth[3].
(20S)-Protopanaxatriol (50-100 mg/kg; p.o.; 25 days; female BALB/c nude mice bearing breast cancer MCF-7 cell) inhibits the growth of MCF-7 breast cancer cells in a nude mice xenograft assay[4]. | Animal Model: | H1975 murine xenograft tumor model | | Dosage: | 10mg/kg | | Administration: | I.p.; daily for four weeks | | Result: | The combined g-PPT and Gefitinib (50 mg/kg/day) treatment clearly reduced p-EGFR and KI67 expression and increased c-Caspase3 expression compared to Gefitinib or g-PPT treatment alone.
|
| | target | Antifection | Glucocorticoid receptor | Oestrogen receptor | LXRα |
| | PROTOPANAXTRIOL Preparation Products And Raw materials |
|